TY - JOUR
T1 - Hyaluronic acid for the treatment of osteoarthritis in all joints except the Knee
T2 - What is the current evidence?
AU - Colen, Sascha
AU - Haverkamp, Daniel
AU - Mulier, Michiel
AU - Van Den Bekerom, Michel P.J.
PY - 2012/3/12
Y1 - 2012/3/12
N2 - Background: The use of intra-articular hyaluronic acid (HA) is a well known treatment in patients with knee osteoarthritis (OA). In other joints, less evidence is available about the efficacy of treatment with intraarticular HA. HA is also used intra-articularly in the metatarsophalangeal-1 joint, the ankle, the hip, the sacroiliac joint, the facet joints, the carpometacarpal-1 joint, the shoulder and the temporo-mandibular joint. In this systematic review we include all prospective studies about the effects of intra-articularHAin the above-mentioned joints. Its use in the knee joint, however, will be discussed in a separate article in this journal. Methods: A systematic review was conducted using databases including MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Clinical Trial Register, and EMBASE. Results: After performing a solid systematic review using a rigid methodology and trying to pool the outcomes of different studies, we noticed that, compared with baseline, there is statistical evidence for a positive effect of intra-articular HA. However, there is limited evidence HA is superior to placebo and no evidence that intra-articular HA is better than corticosteroids or other conservative therapies. Conclusion: Our recommendation for future research is that one should focus on adequately powered randomized trials comparingHAtreatment with other types of intra-articular or conservative treatment.We think it is useless to further perform and publish (large) non-comparative prospective studies about the use of HA in the treatment of problems caused by OA. It is well perceived that HA exerts positive effects in the treatment of OA, but up to now there is no (strong) evidence available that HA is superior to other treatments of OA such as corticosteroids, physiotherapy or other conservative measures.
AB - Background: The use of intra-articular hyaluronic acid (HA) is a well known treatment in patients with knee osteoarthritis (OA). In other joints, less evidence is available about the efficacy of treatment with intraarticular HA. HA is also used intra-articularly in the metatarsophalangeal-1 joint, the ankle, the hip, the sacroiliac joint, the facet joints, the carpometacarpal-1 joint, the shoulder and the temporo-mandibular joint. In this systematic review we include all prospective studies about the effects of intra-articularHAin the above-mentioned joints. Its use in the knee joint, however, will be discussed in a separate article in this journal. Methods: A systematic review was conducted using databases including MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Clinical Trial Register, and EMBASE. Results: After performing a solid systematic review using a rigid methodology and trying to pool the outcomes of different studies, we noticed that, compared with baseline, there is statistical evidence for a positive effect of intra-articular HA. However, there is limited evidence HA is superior to placebo and no evidence that intra-articular HA is better than corticosteroids or other conservative therapies. Conclusion: Our recommendation for future research is that one should focus on adequately powered randomized trials comparingHAtreatment with other types of intra-articular or conservative treatment.We think it is useless to further perform and publish (large) non-comparative prospective studies about the use of HA in the treatment of problems caused by OA. It is well perceived that HA exerts positive effects in the treatment of OA, but up to now there is no (strong) evidence available that HA is superior to other treatments of OA such as corticosteroids, physiotherapy or other conservative measures.
KW - Hyaluronic-acid
KW - Joint-disorders
KW - Osteoarthritis.
UR - http://www.scopus.com/inward/record.url?scp=84857813388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857813388&partnerID=8YFLogxK
U2 - 10.2165/11630830-000000000-00000
DO - 10.2165/11630830-000000000-00000
M3 - Review article
C2 - 22385405
AN - SCOPUS:84857813388
SN - 1173-8804
VL - 26
SP - 101
EP - 112
JO - BioDrugs
JF - BioDrugs
IS - 2
ER -